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Abstract: BACKGROUND Extracorporeal membrane oxygenation (ECMO) support in acute respira-
tory failure may be lifesaving, but bleeding and thromboembolic complications are common. The opti-
mal anticoagulation strategy balancing these factors remains to be determined. This retrospective study
compared two institutional anticoagulation management strategies focussing on oxygenator changes and
both bleeding and thromboembolic events. METHODS We conducted a retrospective observational co-
hort study between 04/2015 and 02/2020 in two ECMO referral centres in Germany in patients receiving
veno-venous (VV)-ECMO support for acute respiratory failure for > 24 h. One centre routinely applied
low-dose heparinization aiming for a partial thromboplastin time (PTT) of 35-40 s and the other routinely
used a high-dose therapeutic heparinization strategy aiming for an activated clotting time (ACT) of 140-
180 s. We assessed number of and time to ECMO oxygenator changes, 15-day freedom from oxygenator
change, major bleeding events, thromboembolic events, 30-day ICU mortality, activated clotting time and
partial thromboplastin time and administration of blood products. Primary outcome was the occurrence
of oxygenator changes depending on heparinization strategy; main secondary outcomes were the occur-
rence of severe bleeding events and occurrence of thromboembolic events. The transfusion strategy was
more liberal in the low-dose centre. RESULTS Of 375 screened patients receiving VV-ECMO support,
218 were included in the analysis (117 high-dose group; 101 low-dose group). Disease severity measured
by SAPS II score was 46 (IQR 36-57) versus 47 (IQR 37-55) and ECMO runtime was 8 (IQR 5-12)
versus 11 (IQR 7-17) days (P = 0.003). There were 14 oxygenator changes in the high-dose group versus
48 in the low-dose group. Freedom from oxygenator change at 15 days was 73% versus 55% (adjusted
HR 3.34 [95% confidence interval 1.2-9.4]; P = 0.023). Severe bleeding events occurred in 23 (19.7%)
versus 14 (13.9%) patients (P = 0.256) and thromboembolic events occurred in 8 (6.8%) versus 19 (19%)
patients (P = 0.007). Mortality at 30 days was 33.3% versus 30.7% (P = 0.11). CONCLUSIONS In this
retrospective study, ECMO management with high-dose heparinization was associated with lower rates
of oxygenator changes and thromboembolic events when compared to a low-dose heparinization strategy.
Prospective, randomized trials are needed to determine the optimal anticoagulation strategy in patients
receiving ECMO support.
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Abstract 
Background: Extracorporeal membrane oxygenation (ECMO) support in acute respiratory failure may be lifesaving, 
but bleeding and thromboembolic complications are common. The optimal anticoagulation strategy balancing these 
factors remains to be determined. This retrospective study compared two institutional anticoagulation management 
strategies focussing on oxygenator changes and both bleeding and thromboembolic events.
Methods: We conducted a retrospective observational cohort study between 04/2015 and 02/2020 in two ECMO 
referral centres in Germany in patients receiving veno-venous (VV)-ECMO support for acute respiratory failure 
for > 24 h. One centre routinely applied low-dose heparinization aiming for a partial thromboplastin time (PTT) of 
35–40 s and the other routinely used a high-dose therapeutic heparinization strategy aiming for an activated clot-
ting time (ACT) of 140–180 s. We assessed number of and time to ECMO oxygenator changes, 15-day freedom from 
oxygenator change, major bleeding events, thromboembolic events, 30-day ICU mortality, activated clotting time 
and partial thromboplastin time and administration of blood products. Primary outcome was the occurrence of 
oxygenator changes depending on heparinization strategy; main secondary outcomes were the occurrence of severe 
bleeding events and occurrence of thromboembolic events. The transfusion strategy was more liberal in the low-dose 
centre.
Results: Of 375 screened patients receiving VV-ECMO support, 218 were included in the analysis (117 high-dose 
group; 101 low-dose group). Disease severity measured by SAPS II score was 46 (IQR 36–57) versus 47 (IQR 37–55) 
and ECMO runtime was 8 (IQR 5–12) versus 11 (IQR 7–17) days (P = 0.003). There were 14 oxygenator changes in the 
high-dose group versus 48 in the low-dose group. Freedom from oxygenator change at 15 days was 73% versus 55% 
(adjusted HR 3.34 [95% confidence interval 1.2–9.4]; P = 0.023). Severe bleeding events occurred in 23 (19.7%) versus 
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Introduction
In refractory acute respiratory failure (ARF), implemen-
tation of veno-venous extracorporeal membrane oxygen-
ation (VV-ECMO) as a rescue strategy may be life-saving 
and is increasingly applied [1]. However, ECMO sup-
port is associated with potentially life-threatening com-
plications, mostly related to either bleeding events or 
thromboembolic complications [2–4]. To minimize such 
events, most centres use unfractionated heparin (UFH)-
based anticoagulation adjusted by partial thromboplastin 
time (PTT), usually within 40–80 s or by activated clot-
ting time (ACT) within 140–180  s [5]. Current guide-
lines advice an ACT-guided approach aiming at 1.5 fold 
increase of normal [6]. With bleeding complications 
occurring in up to 50% of patients, there is a quest for 
alternative anticoagulatory strategies without compro-
mising integrity of the ECMO circuits and risk of throm-
boembolism [2]. Previous studies found lower heparin 
dosing to be generally safe with regards to thromboem-
bolic complications but conclusions are limited by small 
patient numbers [7–9].
Our study aimed to retrospectively compare oxygen-
ator durability, bleeding and thromboembolic events 
between two experienced ECMO centres with consider-
ably different routine anticoagulation strategies but iden-
tical oxygenator change management. We hypothesized, 
that a strategy including low-dose heparin strategy would 
result in similar oxygenator durability and similar throm-
boembolic complications while reducing bleeding events 
compared to a high-dose strategy.
Methods
Design, settings and participants
We conducted a retrospective cohort study including 
patients with severe ARF receiving VV-ECMO support 
between April 2015 and February 2020 at two German 
university hospitals with extensive ECMO experience. 
Both centres routinely used UFH-based anticoagulation, 
but with different intensity, thus enabling us to compare 
a low-dose heparinization strategy aiming for a PTT 
between 35 and 40 s (measured thrice per day using the 
actin FS assay by Siemens) with a high-dose hepariniza-
tion strategy aiming for an ACT between 140 and 180 s 
(measured every 2 h). In the high-dose-group, PTT was 
measured once daily using the Pathrombin SL assay, with 
both tests showing excellent correlation [10]. ECMO 
systems used were Getinge/Maquet RotaFlow or Car-
dioHelp with cannulation of the internal jugular and/or 
femoral veins via 19–25 French cannulas. Standard can-
nulation in the high-dose centre was femoral/jugular 
venous access, while in the low-dose centre a bi-femoral 
venous access was mostly established. For the RotaFlow 
device, the permanent-life-support system was used 
and for the CardioHelp system the HLS Set Advanced 
was used. Both systems were manufactured by Getinge, 
were Bioline-coated and possessed equivalent durability 
[11]. Patients were identified via established ECMO data-
bases at both sites. Inclusion criteria were VV-ECMO 
support ≥ 24  h and provided written informed consent 
by patients or proxy for analysis of clinical data. Exclu-
sion criteria were duration of VV-ECMO support < 24 h; 
external ECMO support > 24  h before referral; addition 
of a third (arterial) cannula within 24  h; age < 18  years; 
acute liver failure with relevant coagulopathy precluding 
heparin administration; missing informed consent and 
medical indication for high-dose anticoagulation in the 
low-dose centre. The study was approved by the institu-
tional review boards at both sites.
Endpoints
The primary endpoint was ECMO oxygenator change 
within the first 15 days. Secondary endpoints were 30-day 
ICU mortality, severe bleeding complications (defined as 
need for intervention or ≥ 10 red blood cell (RBC) trans-
fusions), symptomatic thromboembolic events, number 
of platelet and RBC transfusions during ECMO, adminis-
tered units of UFH during ECMO and coagulation stud-
ies (mean ACT in the high-dose-group, mean PTT in 
both groups).
Transfusion strategies
Absent of overt bleeding, the routine threshold for RBC 
transfusion at the high-dose centre was a haemoglobin 
level < 8 g/dL versus < 9 g/dL in the low-dose group. Rou-
tine threshold for platelet transfusions were < 30.000/µL 
in the high-dose centre versus 70.000/µL in the low-dose 
14 (13.9%) patients (P = 0.256) and thromboembolic events occurred in 8 (6.8%) versus 19 (19%) patients (P = 0.007). 
Mortality at 30 days was 33.3% versus 30.7% (P = 0.11).
Conclusions: In this retrospective study, ECMO management with high-dose heparinization was associated with 
lower rates of oxygenator changes and thromboembolic events when compared to a low-dose heparinization strat-
egy. Prospective, randomized trials are needed to determine the optimal anticoagulation strategy in patients receiv-
ing ECMO support.
Keywords: ECMO, Heparinization, ARDS, Bleeding, Thromboembolism
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centre. With overt bleeding, the routine thresholds for 
platelet transfusion were 50.000/µL (high-dose centre) 
versus 100.000/µL (low-dose centre) but could be indi-
vidualized depending on the clinical scenario, severity 
and site of bleeding. Antithrombin III was substituted 
if antithrombin III levels were < 50% and antifibrino-
lytic agents administered in cases of clinical suspicion 
of hyperfibrinolysis or proof by thromboelastography. 
Bleeding management regarding administration of pro-
thrombin complex concentrates was adjusted by event 
severity at the discretion of the treating physicians and 
was not standardized in both centres.
Indication for oxygenator changes
Oxygenator change was considered in the settings of 
decreasing post-filter  pO2 < 200  mmHg with increasing 
transmembrane pressure gradient (with the CardioHelp 
system), overt circuit thrombosis with thrombi > 5  mm, 
rising D-dimers with progressive thrombocytopenia and 
hyperfibrinolysis with increasing transmembrane pres-
sure gradient, and otherwise unexplained haemolysis 
with increasing transmembrane pressure gradient.
Covariates
Age, admission and discharge dates to ICU, underlying 
reason for ARF, body-mass-index, pre-existing antiplate-
let therapy and comorbidities were obtained from charts. 
Simplified acute physiology score (SAPS) II [12] at day of 
ECMO implantation, Respiratory ECMO Survival Pre-
diction (RESP) score [13], sequential organ failure assess-
ment score (SOFA) [14], heparin doses, ECMO devices 
and settings and coagulation studies were extracted from 
the clinical patient data management system.
Statistical analysis
Continuous data was assessed for normal distribution by 
Shapiro–Wilk-test and group comparison was performed 
using t-test or rank-sum test, as appropriate. Hazard 
ratios for freedom from oxygenator change at 15 days was 
calculated using a multivariable cox regression. Covari-
ables were selected if baseline values were significantly 
unbalanced between the groups or if they were overtly 
physiologically linked to the outcome. We did not include 
number of blood product transfusions and ECMO device 
since they were not independent factors but part of the 
institutional strategy. The final model included age, sex, 
BMI, RESP Score, SAPS II score, SOFA renal sub-score, 
ECMO runtime, sepsis, pre-existing coronary artery dis-
ease, prior treatment with aspirin, mean ECMO flow and 
baseline fibrinogen, d-dimers and antithrombin III levels 
as covariables. Analyses were performed using STATA 




At screening, 375 patients receiving VV-ECMO sup-
port for ARF were identified. A total of 218 patients were 
included in the analysis (117 high-dose group vs. 101 
low-dose group), with details on exclusions provided in 
Fig. 1. The baseline characteristics are shown in Table 1. 
ECMO settings and associated laboratory are shown in 
Table  2. The causes of ARF according the RESP score 
were viral pneumonia (22.5%), bacterial pneumonia 
(30.3%), status asthmaticus (1.8%), trauma/burn (1.8%), 
aspiration pneumonia (7.8%), other acute respiratory 
causes (28.9%) and non-respiratory or chronic respira-
tory causes (6.8%) and were distributed homogenously 
among the groups (p = 0.359). Patients in the high-dose 
group were younger (46  years [IQR 29–55] vs. 54  years 
[interquartile range (IQR) 44–62], P < 0.001) and had 
a lower BMI (26.2  kg/m2 [IQR 22.5–29.4] vs. 29.1 [IQR 
26.0–33.2], P < 0.001. Sepsis was less frequently pre-
sent in the high-dose group (75.2 vs. 95.1%, P < 0.001), 
and primary ARDS was more common in the high-dose 
group (88.9 vs. 68.3%, P < 0.001). While the SAPS-II score 
at day of ECMO implantation was comparable between 
the groups, the RESP-score was higher in the high-dose 
group (1 [IQR – 1 to 3] vs. −0 [−2 to 3], P = 0.002).
Primary endpoint
Overall, there were 14 oxygenator changes in the high-
dose group versus 48 in the low-dose group in 13 versus 
32 patients. Freedom from oxygenator change at 15 days 
was 73% in the high-dose group versus 55% in the low-
dose group (adjusted hazard ratio (HR) 3.34 [95% con-
fidence interval 1.2–9.4 with low-dose heparinization], 
P = 0.023) (Fig. 2), with the entire regression model dis-
played in Fig.  3. Reasons for oxygenator changes were 
decreasing post-filter  paO2 (86% and 59%), thrombus 
formation with increasing D-dimers (14% and 39%), and 
overt haemolysis (0% and 2%). The results were similar 
when analysing freedom from oxygenator change with-
out censoring data at 15  days (adjusted HR 3.28 [95% 
confidence interval 1.2–8.6] with low-dose hepariniza-
tion, P = 0.016).
Secondary endpoints
The overall median of the individual mean ACT in 
the high-dose group was 158  s (IQR 151–165) and the 
median of the mean PTT in the high-dose group was 
48  s (IQR 41–57) versus 38  s (IQR 34–42) in the low-
dose group (P < 0.001) (Fig.  4b, c). The corresponding 
mean units of heparin administered while on ECMO 
were 17,495 (IQR 10,971–24,327) vs. 11,185 (IQR 4,372–
16,750) (P < 0.001) (Fig.  4a). The centre-defined ACT 
and PTT corridors were well-represented in the groups. 
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Additional baseline coagulation parameters are shown 
in Table  2. In the patients who received an oxygenator 
change, the d-dimer foldchange compared to baseline 
was 2.97 (IQR 1.5–8.2) compared to 1.5 (IQR 0.4–4.5), 
in patients who did not undergo oxygenator change 
(P = 0.002).
Severe bleeding was not different and occurred in 
23 (19.7%) of patients in the high-dose group and in 14 
(13.9%) in the low-dose group (P = 0.256) (Table  3). Of 
note, severe intracranial bleeding only occurred in the 
high-dose group with fatal outcome in 5 of 7 cases, while 
3 events of intracranial bleeding in the low-dose group 
were incidental findings on CT without overt neuro-
logical deficit (and where thus not categorized as severe 
bleeding events).
Applying different in-house standards of transfusion 
procedures, the number of RBC unit transfusions were 
significantly lower in the high-dose group compared 
to the low-dose group (6 [IQR 2–10] vs. 8 [IQR 6–19] 
P < 0.001), as were units of platelet transfusions (0 [IQR 
0–1] vs. 4 [0–10], P < 0.001). More patients in the low-
dose group received prothrombin complex concentrates 
(26 [25.7%] vs. 8 [6.8%], p < 0.001) and antithrombin III 
substitution (21 [21%] vs. 8 [6.9%], p = 0.002), while 
administration of tranexamic acid was similar (Table 2). 
All patients who received prothrombin complex 
concentrates had severe coagulopathy in the context of 
planned intervention with high bleeding risk (high-dose 
group: 2/8; low-dose group: 15/26) or significant haemo-
globin-relevant bleeding (high-dose group: 6/8; low-dose 
group 11/26). Pre-ECMO use of antiplatelet therapy was 
not associated with oxygenator change or severe ECMO-
related bleeding events.
Fewer thromboembolic events occurred in the high-
dose group (8 [6.8%]) than in the low-dose group (19 
[19%], P = 0.007). Of note, direct thrombotic events of 
the ECMO circuit (cannula thrombosis n = 1; coagulation 
of the oxygenator n = 2) occurred only in the low-dose 
group (Table 3).
The 30-day ICU mortality was comparable with 33.3% 
(n = 39) in the high-dose versus 30.7% (n = 31) in the low-
dose group (P = 0.11). The main reasons for mortality 
in the high-dose versus low-dose group were cessation 
of therapy due to medical futility in 23 (59%) versus 12 
(38.7%); refractory multiorgan failure in 11 (28.2%) ver-
sus 18 (58.1%), intracranial bleeding in 5 (12.8%) versus 
0; abdominal bleeding complications in 0 versus 1 (3.2%).
Discussion
The key finding of this study is that when compared to an 
ACT-guided high dose heparinization strategy aiming for 
140–180 s, a low dose heparin strategy adjusted by PTT 
216 Received VV-ECMO
support for acute respiratory
failure on medical ICU
117 Were included in the
analysis and had ACT-
guided heparinization with a
goal of 140-180s
13 had oxygenator changes
77 Excluded (No Consent)
6 Excluded (ECMO support for
less than 24h)
6 Excluded (acute liver failure with
desolate coagulation function)
4 Excluded (ECMO support > 24h
before referral)
3 Excluded (triple cannulation
within first 24h)
2 Excluded (age < 18 years)
1 Excluded (missing data)
159 Received VV-ECMO support for
acute respiratory failure on
anaesthesiology ICU
101 Were included in the
analysis and had PTT
guided heparinization with a
goal of 35-40s
32 had oxygenator changes
41 Excluded (did not follow
institutional protocol)
9 Excluded (ECMO support for
less than 24h)
6 Excluded (missing data)
2 Excluded (hereditary
coagulopathy)
High-dose heparin centre Low-dose heparin centre
Fig. 1 Flow chart for patient cohorts by centre / heparinization strategy. The need for written informed consent at the low-dose centre was waved 
by the institutional review board due to the retrospective nature of the study
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aiming for 35–40 s is associated with a three-fold higher 
need for oxygenator changes during VV-ECMO support. 
Although all oxygenator changes in this study were une-
ventful, these procedures are resource-intensive and may 
be potentially life-threatening in patients fully dependent 
on ECMO support.
We initially hypothesized that lower heparin doses 
might be as efficient as therapeutic high dose anticoagu-
lation regarding ECMO oxygenator durability with simi-
lar rates of bleeding events and thromboembolic events. 
However, in our study, low-dose anticoagulation was 
not only associated with a higher need for oxygenator 
changes but also with a higher rate of thromboembolic 
events. Contrarily, bleeding complications, foremost 
intracerebral bleeding events were less common in the 
low-dose group.
Between the two centres, there were overt and signifi-
cant differences regarding number of transfusions for 
both RBC and platelet transfusions with considerably 
greater amounts given in the low-dose group. It is impor-
tant to point out that these changes rather reflect the 
more liberal transfusion strategy in the low-dose centre 
than bleeding severity. At the same time, prothrombin 
complex concentrates and antithrombin III preparations 
were also more commonly administered in the low-dose 
group, where peri-operative patients were treated more 
often. In studies unrelated to ECMO, RBC transfusion 
have been shown to increase platelet responsiveness 
especially with decreased platelet counts and overall inci-
dence of thromboembolic events [15–17]. With ECMO 
support, both transfusions of platelets and RBC have 
been reported as independent risk factors for mortality 
[18, 19]. Therefore, differences in the transfusion strat-
egy might have influenced the outcome in the current 
study and are not exclusively explained by hepariniza-
tion. Future prospective RCT evaluating the optimal 
anticoagulation strategy in patients receiving ECMO sup-
port should be planned with pre-specified transfusions 
strategies.
The findings from our study contradict previous 
results from a small prospective trial (n = 10) where 
heparinization aiming for a PTT of 45–55 s (vs. 35–40 s 
in the present study) was compared to a standardized 
dose of 10U / kg / hour summing up to comparable 
mean doses in the high-dose group of the present study 
[20] showing no differences in oxygenator changes 
Table 1 Baseline characteristics
ARDS acute respiratory distress syndrome, BMI Body mass index, ECMO extracorporeal membrane oxygenation, IQR interquartile range, RESP Respiratory ECMO 
Survival Prediction score, SAPS II Simplified acute physiology score II, SOFA sequential organ failure assessment
* Defined by sequential organ failure assessment liver subscore of ≥ 2
ALL
( n = 218)
High-dose group
( n = 117)
Low-dose group
( n = 101)
P value
Baseline Characteristics
 Gender, n (%), male 153 (70.2) 85 (72.6) 68 (67.3) 0.392
 Age, median (IQR), years 49 (38–60) 46 (29–55) 54 (44–62)  < 0.001
 BMI, median (IQR), kg/m2 27.7 (24.2–30.9) 26.2 (22.5–29.4) 29.1 (26.0–33.2)  < 0.001
 SAPS II (IQR) 47 (37–56) 46 (36–57) 47 (37–55) 0.871
 SOFA Score (IQR) 9 (8–10) 9 (7–10) 9 (8–10) 0.650
  Respiration-sub-score 4 4 4
  Coagulation-sub-score 0 (0–1) 0 (0–1) 0 (0–2) 0.573
  Liver-sub-score 0 (0–1) 0 (0–2) 0 (0–1) 0.059
  Cardiovascular-sub-score 4 (3–4) 4 (3–4) 4 (3–4) 0.151
  Renal-sub-score 1 (0–4) 1 (0–4) 1 (0–2) 0.004
 RESP-Score (IQR) 1 (-2–3)) 1 (-1–3) 0 (-2–3) 0.002
 Sepsis, n (%) 184 (84.4) 88 (75.2) 96 (95.1)  < 0.001
 Primary ARDS, n (%) 173 (79.4) 104 (88.9) 69 (68.3)  < 0.001
 Immunocompromised, n (%) 68 (31.2) 31 (26.5) 37 (36.6) 0.107
 Liver failure* 53 (24.3) 34 (29.1) 19 (18.8) 0.079
Comorbidities, n (%)
  Diabetes mellitus 42 (19.4) 19 (16.4) 23 (22.8) 0.234
  Arterial hypertension 76 (35.0) 34 (29.3) 42 (41.6) 0.059
  Coronary artery disease 21 (9.6) 7 (6.0) 14 (13.9) 0.049
  Malignancy (solid) 8 (3.7) 2 (1.7) 6 (5.9) 0.098
  Malignancy (Hematologic) 14 (6.4) 8 (6.8) 6 (5.9) 0.788
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and bleeding events with considerable chances for 
underpowering. A longitudinal single-centre pre-post 
designed retrospective trial (n = 40) showed similar 
survival to decannulation rates, bleeding events and 
thromboembolic complications [21], but interestingly 
the ACTs in both groups were rather high (167  s vs. 
189 s) compared to our cohort. Another mixed cohort 
including 22 patients with VV-ECMO compared hep-
arinization guided by ACT (140–160  s vs. 180–220) 
and consistently found fewer bleeding events and simi-
lar rates of oxygenator changes [22], also aiming for 
higher ACT-prolongation than in our cohort. The lack 
of uniform anticoagulation strategies and outcome 
definitions across all studies render comparison of 
event rates difficult [23].
Beside mere heparin dosage, temporary interrup-
tion of heparin (e.g. in response to bleeding) may create 
a hypercoagulable milieu, thereby increasing the risk of 
clotting and oxygenator failure [24, 25], which might have 
influenced the results of the present study. Case series 
and smaller retrospective studies reported feasibility of 
heparin-free ECMO support in cases of trauma or severe 
bleeding [26–29] and intermittent subcutaneous admin-
istration of heparin to avoid heparin pauses [25], but the 
optimal management strategies in these particularly chal-
lenging situations needs to be prospectively investigated 
Table 2 ECMO settings and relevant coagulation factors
ECMO extracorporeal membrane oxygenation, IQR interquartile range, PCC prothrombin complex centrates
ALL
( n = 218)
High-dose group
( n = 117)
Low-dose group
( n = 101)
P value
ECMO device  < 0.001
 CardioHelp 31 (26.5) 99 (98)
 RotaFlow 86 (73.5) 2 (2)
Canula site out
 Jugular vein 3 (1.4) 3 (2.6) 0
 Femoral vein 215 (98.6) 114 (97.4) 101 (100)
Canula site in
 Jugular vein 135 (61.9) 113 (96.6) 22 (21.8)
 Subclavian vein 2 (0.9) 2 (1.7) 0
 Femoral vein 81 (37.2) 2 (1.7) 79 (78.2)
Canula size out 23 (23–35) 23 (23–23) 25 (25–25)  < 0.001
Canula size in 17 (17–23) 17 (17–17) 23 (21–25)  < 0.001
ECMO runtime, median (IQR), days 9 (5–14) 8 (5–12) 11 (7–17) 0.003
ECMO flow, median (IQR), liter per minute 3.8 (3.3–4.4) 3.5 (2.8–3.9) 4.4 (3.8–4.9)  < 0.001
Days from mechanical ventilation to ECMO implantation, 
median (ICR)
1 (0–3) 1 (0–3) 1 (0–4) 0.185
Antiplatelet therapy pre-ECMO
Aspirin 31 (14) 13 (11) 18 (18) 0.157
P2Y12-inhibitors 6 (3) 2 (2) 4 (4) 0.311
Antiplatelet therapy during ECMO, n (%)
Aspirin 27 (12) 9 (8) 18 (18) 0.024
P2Y12-inhibitors 5 (2) 0 5 (5) 0.015
Baseline fibrinogen, g/L (IQR) 4.7 (3.3–6.2) 6.7 (3.3–6.4) 4.8 (3.4–6.1) 0.611
Minimal fibrinogen, g/L (IQR) 2.2 (1.4–3.4) 2.5 (1.6–3.5) 2.0 (1.2–3.4) 0.030
Baseline d-dimers, mg/L (IQR) 7.6 (3.6–15.4) 5.4 (2.6–12.7) 8.3 (4.4–16.5) 0.010
Maximum d-dimers, mg/L (IQR) 30 (19.3–35) 28.5 (13–30) 35 (33.4–35)  < 0.001
Baseline antithrombin III, % (IQR) 67 (53–86) 79 (60–93) 60 (44–75)  < 0.001
Minimum antithrombin III, % (IQR) 59 (45–76) 69 (56–84) 48 (37–62)  < 0.001
Antithrombin III substitution, n (%) 29 (13.3) 8 (6.8) 21 (21) 0.002
Baseline thrombocyte count, thousand / µL (IQR) 174 (101–265) 167 (109–269) 183 (97–263) 0.878
Minimum thrombocyte count, thousand / µL (IQR) 62 (36–88) 65 (33–106) 60 (40–81) 0.868
Received PCC, n (%) 36 (16.5) 8 (6.8) 26 (25.7)  < 0.001
Received tranexamic acid, n (%) 113 (51.8) 61 (52.1) 52 (51.5) 0.924
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and lies beyond the scope of the current retrospective 
study.
In recent years, more centres integrated anti-Xa lev-
els alongside ACT or PTT in their routine coagulation 
monitoring during ECMO support following promising 
results mainly in paediatric populations and better reflec-
tion of heparin concentrations [30–33]. Since inflamma-
tion can influence ACT measurements [34] the ECMO 
centres of the current study also utilize anti-Xa levels 
alongside thromboelastography and single clotting factor 
analysis where coagulation state is uncertain, and PTT 
or ACT seems out of line with heparin dosing. However, 
longer turn-around time and varying 24/7 availability 
of anti-Xa measurements are limiting factors and 97% 
of ECMO centres were still using ACT for heparin dose 
adjustments in 2014 [35]. Since current ELSO guidelines 
recommend ACT and PTT for measuring heparin effects 
[6], the analysis of different heparinization strategies 
based on these assays provide valuable information for 
intensivists caring for ECMO patients. Yet, we acknowl-
edge that anti-Xa levels may be a more appropriate meas-
urement of heparin effects than ACT or PTT in critically 
ill patients.
Limitations of this study were inherent to the ret-
rospective design and the comparison of two centres, 
which render the data subject to substantial potential 
bias, including different bleeding management strategies, 
different ECMO devices, cannulation sites and patient 
populations. Our data thus needs prospective validation 
with uniform strategies for bleeding management, trans-
fusion strategies and ECMO configuration to derive solid 
recommendations.
Conclusion
In this two-centre cohort study, the institutional strategy 
with a high-dose heparinization during ECMO support 
was associated with lower rates of oxygenator changes 
and thromboembolic events, compared to the strategy 
with low-dose heparinization. Prospective randomized 
validation with standardized bleeding management and 
ECMO settings is needed to confirm these findings.
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Fig. 2 Freedom of oxygenator-change at 15 days between high-dose and low-dose heparinization groups. Data is censored for decannulation or 
mortality. HR hazard ratio, CI confidence interval. aAdjusted for age, gender, body-mass-index, Respiratory ECMO Survival Prediction (RESP) score, 
Simplified acute physiology score II, sequential organ failure assessment renal sub-score, ECMO runtime, sepsis, coronary artery disease, prior aspirin 
use, mean ECMO blood flow, baseline fibrinogen, d-dimer and antithrombin III levels.
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Fig. 3 Multivariable cox regression model for oxygenator change. BMI body mass index, CAD coronary artery disease, RESP Respiratory ECMO 
Survival Prediction score, SAPS simplified acute physiology score, SOFA sequential organ failure assessment
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Fig. 4 Mean units of UFH administered per day (a); mean partial thromboplastin time (PTT) during ECMO (b) and mean activated clotting time 
(ACT) in the high-dose (HD) UFH group (c). ECMO extracorporeal membrane oxygenation, HD high dose heparin groups, LD low dose heparin 
group, PTT partial thromboplastin time, ACT activated clotting time, UFH unfractionated heparin
Table 3 Secondary outcomes








Severe bleeding events, n (%) 37 (17.0) 23 (19.7) 14 (13.9) 0.256
 Gastrointestinal / intrabdominal 12 (5.5) 5 (4.3) 7 (6.9)
 Intracranial 7 (3.2) 7 (6.0) 0
 Intrathoracic 16 (7.3) 10 (8.5) 6 (5.9)
 Cannula site 2 (0.9) 1 (0.9) 1 (1.0)
 Ear-nose-throat 1 (0.5) 1 (0.8) 0
RBC transfusions 7 (3–13) 6 (2–10) 8 (6–19)  < 0.001
Platelet transfusions 1 (0–5) 0 (0–1) 4 (0–10)  < 0.001
Thromboembolic events, n (%) 27 (12.4) 8 (6.8) 19 (19) 0.007
 Intraabdominal embolism / thrombosis 5 (2.3) 3 (2.5) 2 (2.0)
 Venous thrombosis 12 (5.5) 4 (3.4) 7 (6.9)
 Pulmonary embolism 3 (1.8) 1 (0.9) 2 (2.0)
 Peripheral arterial embolism 2 (0.9) 0 2 (2.0)
 ECMO filter embolism 3 (1.8) 0 3 (3.0)
 ECMO cannula thrombosis 1 (0.5) 0 1 (1.0)
 Ischemic stroke 2 (0.9) 0 2 (2.0)
 Heparin-induced thrombocytopenia, n (%) 3 (1.4) 1 (0.9) 2 (2.0)
30-day ICU mortality 70 (32.1) 39 (33.3) 31 (30.7) 0.110
Overall ICU mortality 91 (41.7) 47 (40.2) 44 (43.6) 0.612
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